Search Results for "Hydrocodone Bitartrate 7 5 Mg"

17:15 EST 18th January 2017 | BioPortfolio

Matching Channels


Matching News

FDA approves Lupin’s hydrocodone bitartrate, acetaminophen tablets

David SalazarThe Food and Drug Administration has approved a generic of Mikart’s hydrocodone bitartrate and acetaminophen tablets from Gavis Pharmaceuticals, Lupin’s U.S. subsidiary, the c...

Teva Release: Company Receives FDA Approval For VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated With Proprietary Abuse Deterrence Technology

  Life Sciences Jobs   ...

FDA approves Lupin's generic painkiller

Lupin Somerset's generic version of Allergan Sales' Norco tablets, or hydrocodone bitartrate and acetaminophen, has been appr -More- 

BRIEF-Lupin Ltd receives FDA approval for analgesic drugs

* Lupin receives FDA approval for hydrocodone bitartrate and acetaminophen tablets Source text: Further company coverage:

BRIEF-Teva receives FDA approval for VANTRELATM ER

* Teva receives FDA approval for VANTRELATM ER (hydrocodone bitartrate) extended-release tablets formulated with proprietary abuse deterrence technology Source text for Eikon: Further company covera...

ED Hydrocodone/Acetaminophen Prescriptions in the VA

How have prescribing patterns for hydrocodone/acetaminophen among veterans changed in recent years? Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health

Abuse-Deterrent Hydrocodone ER Safe, Effective in Back Pain

An extension study shows that patients receiving an investigational abuse-deterrent hydrocodone (Vantrela ER) maintained pain relief for 6 months and that the drug was still safe. Medscape Medical N...

FDA warns against combining opioids and benzodiazepines

The FDA has issued a warning regarding the combined use of opioids and benzodiazepines, which may result in serious adverse effects such as difficult or slowed breathing and death, according to a pres...

Matching PubMed Articles

Hydrocodone Bitartrate ER (Hysingla(®) ER): A Review in Chronic Pain.

Hydrocodone bitartrate extended-release (Hysingla(®) ER; referred to hereafter as hydrocodone ER) was the first single-entity hydrocodone formulation recognized by the US FDA as having abuse-deterren...

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

 A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER [HYD]) is available for the treatment of chronic pain in appropriate patients. This study e...

Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone.

Immediate-release (IR) hydrocodone is the most widely prescribed opioid in the United States; however, little is known about the utilization patterns and duration of opioid use among patients prescrib...

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.

Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential effect can have significant detrimental ...

Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.

The U.S. Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products (HCPs) in an attempt to mitigate the prescription opioid epidemic. Many in the medical and pharmacy communit...

Search Whole site using Google

Quick Search
Advertisement Advertisement